118 related articles for article (PubMed ID: 37815173)
1. Correction to: AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20).
Oncologist; 2024 Apr; 29(4):e579. PubMed ID: 37815173
[No Abstract] [Full Text] [Related]
2. AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20).
Suh KJ; Ryu MH; Zang DY; Bae WK; Lee HS; Oh HJ; Kang M; Kim JW; Kim BJ; Mortimer PGS; Kim HJ; Lee KW
Oncologist; 2023 Sep; 28(9):e823-e834. PubMed ID: 37036671
[TBL] [Abstract][Full Text] [Related]
3. A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.
Choudhury AD; Higano CS; de Bono JS; Cook N; Rathkopf DE; Wisinski KB; Martin-Liberal J; Linch M; Heath EI; Baird RD; García-Carbacho J; Quintela-Fandino M; Barry ST; de Bruin EC; Colebrook S; Hawkins G; Klinowska T; Maroj B; Moorthy G; Mortimer PG; Moschetta M; Nikolaou M; Sainsbury L; Shapiro GI; Siu LL; Hansen AR
Clin Cancer Res; 2022 Jun; 28(11):2257-2269. PubMed ID: 35247924
[TBL] [Abstract][Full Text] [Related]
4. TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
Vicier C; Sfumato P; Isambert N; Dalenc F; Robert M; Levy C; Rezai K; Provansal M; Adélaïde J; Garnier S; Guille A; Carbuccia N; Popovici C; Charafe-Jauffret E; Chaffanet M; Birnbaum D; Pakradouni J; Bertucci F; Boher JM; Sabatier R; Gonçalves A
Eur J Cancer; 2021 Dec; 159():205-214. PubMed ID: 34781168
[TBL] [Abstract][Full Text] [Related]
5. Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
Kim BJ; Jee HJ; Rha SY; Han HS; Ryu MH; Park SH; Kim JG; Bae WK; Lee KW; Oh DY; Byun JH; Kim DS; Suh YJ; An H; Zang DY
Gastric Cancer; 2022 May; 25(3):609-618. PubMed ID: 35015188
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16).
Han HS; Kim BJ; Jee HJ; Ryu MH; Park SH; Rha SY; Kim JG; Bae WK; Lee KW; Oh DY; Kim IH; Sym SJ; Oh SY; Kim HS; Byun JH; Kim DS; Suh YJ; An H; Zang DY
Ther Adv Med Oncol; 2021; 13():17588359211042812. PubMed ID: 34552667
[TBL] [Abstract][Full Text] [Related]
7. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
Williams NO; Quiroga D; Johnson C; Brufsky A; Chambers M; Bhattacharya S; Patterson M; Sardesai SD; Stover D; Lustberg M; Noonan AM; Cherian M; Bystry DM; Hill KL; Chen M; Phelps MA; Grever M; Stephens JA; Ramaswamy B; Carson WE; Wesolowski R
Ther Adv Med Oncol; 2023; 15():17588359231217976. PubMed ID: 38152697
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
Jung M; Ryu MH; Oh DY; Kang M; Zang DY; Hwang IG; Lee KW; Kim KH; Shim BY; Song EK; Sym SJ; Han HS; Park YL; Kim JS; Lee HW; Lee MH; Koo DH; Song HS; Lee N; Yang SH; Choi DR; Hong YS; Lee KE; Maeng CH; Baek JH; Kim S; Kim YH; Rha SY; Cho JY; Kang YK
Gastric Cancer; 2018 Sep; 21(5):819-830. PubMed ID: 29427038
[TBL] [Abstract][Full Text] [Related]
9. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas.
Ueda S; Satoh T; Gotoh M; Gao L; Doi T
Oncologist; 2015 May; 20(5):493-4. PubMed ID: 25888272
[TBL] [Abstract][Full Text] [Related]
10. A phase Ib/II study of fruquintinib in combination with paclitaxel as the second-line therapy for advanced gastric cancer.
Zhang Y; Wang ZX; Shen L; Li J; Huang J; Su WG; Zhang DS; Xu RH
Cancer Commun (Lond); 2023 Jan; 43(1):150-153. PubMed ID: 36331272
[No Abstract] [Full Text] [Related]
11. Phase II Study of S-1 Monotherapy as a First-line, Combination Therapy of S-1 plus Cisplatin as a Second-line, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma: Phase II Study of S-1, S-1 plus Cisplatin, and Weekly Paclitaxel in Patients with Advanced Gastric Carcinoma.
Rino Y; Yukawa N; Wada N; Suzuki M; Murakami H; Yamada T; Nakayama H; Yamamoto N; Sato T; Yamada R; Ohshima T; Masuda M; Imada T
Clin Med Oncol; 2008; 2():375-83. PubMed ID: 21892302
[TBL] [Abstract][Full Text] [Related]
12. Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
Kawamoto Y; Komatsu Y; Yuki S; Sawada K; Muranaka T; Harada K; Nakatsumi H; Fukushima H; Ishiguro A; Dazai M; Hatanaka K; Nakamura M; Iwanaga I; Uebayashi M; Sogabe S; Kobayashi Y; Miyagishima T; Ono K; Sakamoto N; Sakata Y
BMC Cancer; 2017 Dec; 17(1):837. PubMed ID: 29221445
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer.
Gadgeel SM; Shields AF; Heilbrun LK; Labadidi S; Zalupski M; Chaplen R; Philip PA
Am J Clin Oncol; 2003 Feb; 26(1):37-41. PubMed ID: 12576922
[TBL] [Abstract][Full Text] [Related]
14. Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors.
Lee MX; Wong ALA; Ow S; Sundar R; Tan DSP; Soo RA; Chee CE; Lim JSJ; Yong WP; Lim SE; Goh BC; Wang L; Lee SC
Target Oncol; 2022 Mar; 17(2):141-151. PubMed ID: 35195837
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Hancox U; Cosulich S; Hanson L; Trigwell C; Lenaghan C; Ellston R; Dry H; Crafter C; Barlaam B; Fitzek M; Smith PD; Ogilvie D; D'Cruz C; Castriotta L; Wedge SR; Ward L; Powell S; Lawson M; Davies BR; Harrington EA; Foster E; Cumberbatch M; Green S; Barry ST
Mol Cancer Ther; 2015 Jan; 14(1):48-58. PubMed ID: 25398829
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
17. A Phase III Study to Compare the Efficacy and Safety of Paclitaxel Versus Irinotecan in Patients with Metastatic or Recurrent Gastric Cancer Who Failed in First-line Therapy (KCSG ST10-01).
Lee KW; Maeng CH; Kim TY; Zang DY; Kim YH; Hwang IG; Oh SC; Chung JS; Song HS; Kim JW; Jeong SJ; Cho JY
Oncologist; 2019 Jan; 24(1):18-e24. PubMed ID: 30126861
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
Kim CG; Jung M; Kim HS; Lee CK; Jeung HC; Koo DH; Bae WK; Zang DY; Kim BJ; Kim H; Yun UJ; Che J; Park S; Kim TS; Kwon WS; Park J; Cho SW; Nam CM; Chung HC; Rha SY
J Clin Oncol; 2023 Sep; 41(27):4394-4405. PubMed ID: 37364218
[TBL] [Abstract][Full Text] [Related]
19. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
[TBL] [Abstract][Full Text] [Related]
20. A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.
Rodon J; Curigliano G; Delord JP; Harb W; Azaro A; Han Y; Wilke C; Donnet V; Sellami D; Beck T
Oncotarget; 2018 Aug; 9(60):31709-31718. PubMed ID: 30167089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
